CREMα has been established as a central contributor to tissue-specific gene regulation in immune cells. Secondary to increased expression of CREMα in T cells from SLE patients, CREMα harbors the potential of being utilized as a disease biomarker and/or therapeutic target. However, several central questions remain to be answered in future studies, many of which are outlined below.
